Sunpeaks Ventures Inc. (SNPK), through its wholly owned subsidiary, Healthcare Distribution Specialists LLC (HDS), is a nationally focused, value-added distributor of specialty drugs and over-the-counter (OTC) branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized OTC multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.
|Share Statistics (22-Mar-12)
|Avg Vol (3m):
Source: Reuters.com, SEC Filings.
Shares in Sunpeaks Ventures Inc. (SNPK) gained 12.63% to close Monday trade at $0.66, extending gains into a third day. Over 9 million shares exchanged hands during the session, versus the 10-day average of nearly 22 million.
Sunpeaks, together with its wholly owned subsidiary Healthcare Distribution Specialists LLC (HDS), is a nationally focused, value-added distributor of specialty drugs and over-the-counter (OTC) branded multivitamins to the healthcare provider market. The company in February completed its acquisition of HDS, which owns and market Clotamin, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin, a popular blood thinner that has a long list of known adverse drug and food interactions.
SNPK claims Clotamin to be the world’s first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin or other anticoagulants (blood thinners).
The Company on Wednesday announced it will be participating in the Diet, Vitamin & Sports Nutrition Expo, which will be held at the Westin Beach Resort & Spa in Fort Lauderdale, Florida on July 15-17, 2012. As part of the expo, HDS is scheduled to conduct one-on-one meetings and planning sessions with national pharmacies and retailers, including Costco, CVS, GNC, Kmart, Vitamin World and many others.
“Participating in this event is going to give us one-on-one time with numerous companies. Given the amount of Warfarin that is sold through these companies, it is our belief they will be able to understand the value proposition of carrying Clotamin in their stores,” commented Mackie Barch, CEO of SNPK. “Although Clotamin already has a nationwide distribution footprint, the potential addition of these key players can only increase product awareness and continue to build sales and shareholder value.”
Providing an update regarding the development and market potential of Clotamin, CEO Barch recently stated if the Company is able to penetrate just 5% of the market for Warfarin, which is one of the top 20 most prescribed drugs in the U.S. – with over 32 million prescriptions being written each year for about 6 to 7 million patients, Clotamin sales could potentially surpass $25 million annually.
SNPK believes the anticoagulants market will surpass $11.2 billion by the year 2015, attributable to an aging global population, rising incidence of cardiovascular diseases, cancers, and acute hip and knee complications, as well as emergence of innovative therapeutics targeting new and previously targeted clotting factors. SNPK cited BioMed Trends in a report released by Global Industry Analysts Inc.
SNPK has released a string of news on its Clotamin product over the last few weeks.
Most recently, the Company announced that Clotamin will soon be available at Sedano’s Supermarkets across South and Central Florida. “The addition of this established regional retailers adds to the growing list of Clotamin distributors and should be a boost for expanding and sustaining Clotamin sales in the South and Central Florida region,” commented Mackie Barch, CEO of SNPK. Just a week ago, SNKP announced that Clotamin will soon be available in nearly 70 Discount Drug Mart (DDM) retail locations in Ohio, and will also included in the Pro Points Program — DDM’s signature customer rewards program
Investors also recently welcomed the news that the Company has inked a deal with former All-Star player and professional basketball coach, Paul Silas, as national spokesperson for Clotamin. The Company previously said that it intends to launch a national ad campaign featuring the famous player/coach designed to drive Clotamin into new markets and distribution channels upon successful conclusion of negotiations.
To improve its overall capital structure and to increase shareholder value, SNPK earlier this month canceled 50 million common shares of its authorized stock. The canceled shares were previously held by CEO Barch.
No financial data is available for SNPK.
No direct competitor comparison
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.
To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).
We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.